Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, & Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients With Polycythemia Vera

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

December 21, 2022

Feat. H. Erba

Feat. J. Mccloskey

Indy Hematology Review

Indy Hematology Review

Integrity CE

T. Bat, A. Tefferi

University of Colorado Division of Hematology

Insights from 2023 ASH Annual Meeting

T. Bat, A. Tefferi

Feat. C. Harrison

Indy Hematology Review

Yale Cancer Center

N. Podoltsev

Feat. C. Harrison

T. Bat, A. Tefferi

Insights from 2023 ASH Annual Meeting

Insights from 2023 ASH Annual Meeting

Prithviraj Bose

Krisstina Gowin

Monia Marchetti

ASH 2022 Conference Coverage

Login

Login

Join VuMedi

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, & Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients With Polycythemia Vera

A proven CD123 targeted therapy for BPDCN

New Approval for Frontline Consolidation in Patients with CD19-posit…

Related Videos

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Current Approaches in the Treatment of Myeloproliferative Neoplasms

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Experts Discuss Pros and Cons of Treatment Approaches in PV

2024 Updates in PV/ET

Treatment Strategies for Hematocrit Control in PV

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Review of Myeloproliferative Neoplasms

Myeloid Malignancies: Hot Topics in 2024

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Importance of Early Management of Patients with Myelofibrosis (MF)

Optimizing the Management of Patients with Polycythemia Vera (PV)

Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

When to Switch From Hydroxyurea to Ruxolitinib in PV

Counseling Patients With Newly Diagnosed PV or ET

CYTO-PV Study: Importance of Hematocrit Control and Early Interventi…

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…